About Huahai Pharmaceutical
Huahai Pharmaceutical is a company based in Taizhou (China) founded in 1989.. The company has 9,060 employees as of December 31, 2024. Huahai Pharmaceutical operates in a competitive market with competitors including Almac Group, Indoco Remedies, Concord Biotech, BDR Pharmaceuticals Internationals and Aurobindo Pharma, among others.
- Headquarter Taizhou, China
- Employees 9060 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Zhejiang Huahai Pharmaceutical Co., Ltd. Class A
-
Annual Revenue
$1.29 B (USD)14.84as on Dec 31, 2024
-
Net Profit
$153.44 M (USD)34.74as on Dec 31, 2024
-
EBITDA
$341.13 M (USD)19.53as on Dec 31, 2024
-
Latest Funding Round
-
Investors
-
Employee Count
9060
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Huahai Pharmaceutical
Huahai Pharmaceutical is a publicly listed company on the SSE with ticker symbol 600521 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Huahai Pharmaceutical
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Huahai Pharmaceutical
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Huahai Pharmaceutical
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Huahai Pharmaceutical Comparisons
Competitors of Huahai Pharmaceutical
Huahai Pharmaceutical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Almac Group, Indoco Remedies, Concord Biotech, BDR Pharmaceuticals Internationals and Aurobindo Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Integrated CDMO services for biopharma R&D and manufacturing are offered.
|
|
| domain | founded_year | HQ Location |
APIs manufacturing and formulation services are provided in therapeutic segments.
|
|
| domain | founded_year | HQ Location |
APIs and enzymes are manufactured through fermentation by the CDMO.
|
|
| domain | founded_year | HQ Location |
APIs and finished products are developed and manufactured.
|
|
| domain | founded_year | HQ Location |
Generic biocatalytic solutions are provided for pharmaceutical applications.
|
|
| domain | founded_year | HQ Location |
APIs and peptides are developed and manufactured by Asymchem.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Huahai Pharmaceutical
Frequently Asked Questions about Huahai Pharmaceutical
When was Huahai Pharmaceutical founded?
Huahai Pharmaceutical was founded in 1989.
Where is Huahai Pharmaceutical located?
Huahai Pharmaceutical is headquartered in Taizhou, China. It is registered at Taizhou, Jiangsu, China.
Who is the current CEO of Huahai Pharmaceutical?
Baohua Chen is the current CEO of Huahai Pharmaceutical.
How many employees does Huahai Pharmaceutical have?
As of Dec 31, 2024, the latest employee count at Huahai Pharmaceutical is 9,060.
What is the annual revenue of Huahai Pharmaceutical?
Annual revenue of Huahai Pharmaceutical is $1.29B as on Dec 31, 2024.
What does Huahai Pharmaceutical do?
Huahai Pharmaceutical was established in 1989 in Taizhou, China, as a pharmaceutical group focused on APIs, formulations, and intermediates. Eleven subsidiaries operate in the United States, Shanghai, Hangzhou, and Linhai. Pril products such as captopril and enalapril, used as ACE inhibitors, are supplied globally, with the company positioned as a major provider. A broader API portfolio addresses conditions including Alzheimers disease, diabetes, and AIDS.
Who are the top competitors of Huahai Pharmaceutical?
Huahai Pharmaceutical's top competitors include Concord Biotech, BDR Pharmaceuticals Internationals and Almac Group.
Is Huahai Pharmaceutical publicly traded?
Yes, Huahai Pharmaceutical is publicly traded on SSE under the ticker symbol 600521.
What is Huahai Pharmaceutical's ticker symbol?
The ticker symbol of Huahai Pharmaceutical is 600521 on SSE.